Non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase 1 and cyclooxygenase 2 (IC50 values are 12 and 80 μM respectively). Active isomer of ibuprofen.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 206.28. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.85 mL||24.24 mL||48.48 mL|
|5 mM||0.97 mL||4.85 mL||9.7 mL|
|10 mM||0.48 mL||2.42 mL||4.85 mL|
|50 mM||0.1 mL||0.48 mL||0.97 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Kato et al (2001) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J.Pharm.Pharmacol. 53 1679 PMID: 11804398
If you know of a relevant reference for (S)-(+)-Ibuprofen, please let us know.
View Related Products by Product Action
Keywords: (S)-(+)-Ibuprofen, supplier, Cyclooxygenase, inhibitors, inhibits, COX-1, COX-2, Oxygenases, Oxidases, Cyclooxygenase, Tocris Bioscience
Citations for (S)-(+)-Ibuprofen
Citations are publications that use Tocris products.
Currently there are no citations for (S)-(+)-Ibuprofen. Do you know of a great paper that uses (S)-(+)-Ibuprofen from Tocris? If so please let us know.
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.